MARKET

SONN

SONN

Sonnet Biotherapeutc Hldng Inc
NASDAQ
4.890
+0.420
+9.40%
Opening 10:42 07/09 EDT
OPEN
4.520
PREV CLOSE
4.470
HIGH
4.930
LOW
4.320
VOLUME
548.72K
TURNOVER
--
52 WEEK HIGH
10.02
52 WEEK LOW
1.080
MARKET CAP
15.48M
P/E (TTM)
-0.4309
1D
5D
1M
3M
1Y
5Y
1D
3 Penny Stocks to Watch Now, 7/8/25
TipRanks · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at SONN last week (0630-0704)?
Weekly Report · 2d ago
US Stocks Likely To Open Lower After A Week Of Records: Tesla In Focus As Elon Musk Announces America Party
Benzinga · 2d ago
Why Apogee Therapeutics Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
More
About SONN
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Webull offers Sonnet Biotherapeutics Holdings Inc stock information, including NASDAQ: SONN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SONN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SONN stock methods without spending real money on the virtual paper trading platform.